HIIFS
SAGE

Harel Insurance Investments & Financial Services’s Sage Therapeutics SAGE Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-161
Closed -$26K – 494
2018
Q1 		$26K Buy
+161
New +$27.3K ﹤0.01% 368

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Harel Insurance Investments & Financial Services's SAGE Position: Q2 2018 in Review

Harel Insurance Investments & Financial Services sold out of Sage Therapeutics (SAGE) in Q2 2018, closing a stake of 161 shares — an estimated $26K sold.

Harel Insurance Investments & Financial Services first reported a position in SAGE in Q1 2018 and held it in 1 quarter. The position peaked at $26K in Q1 2018. 269 funds tracked by Wall St. Rank hold SAGE as of Q2 2018.

  • Harel Insurance Investments & Financial Services reported no remaining Sage Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Harel Insurance Investments & Financial Services sold 161 Sage Therapeutics shares in Q2 2018, an estimated $26K.
  • Harel Insurance Investments & Financial Services first reported a position in Sage Therapeutics in Q1 2018 and held it in 1 quarter.
  • Harel Insurance Investments & Financial Services's Sage Therapeutics position peaked at $26K in Q1 2018.
  • 269 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2018.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q2 2018, filed 30 Jul 2018.